Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: A retrospective european multi‐center analysis
Abstract
This is a retrospective analysis of children with metastatic soft tissue sarcoma (STS) registered in the major European STS studies: the SIOP MMT 75, the German CWS 1981 and 1986 studies, the Italian STS study, and the United Kingdom Children's Cancer Study Group centres in Britain. One hundred forty-six patients out of 164 were evaluable in this analysis. The median age was 7 years (1-18) and the male/female ratio was 1.3:1. The median follow-up was 80 months (7-171). The most common site of the primary tumor was the extremity (28%), which correlated well with the high preponderance (39%) of the alveolar type of RMS (aRMS). There was no dominant combination of metastatic sites and the most common single organ with metastasis was the lung (41%). Since the therapy depended on the country and period in which the patient was treated, we did not analyse the outcome and therapy together. Complete remission was achieved in 50% of the cases. Those with aRMS had a good chance of achieving CR (61%) but the majority of these patients relapsed (78%). The median time needed to relapse was 243 days (53 days to 47 months) for all patients. Analysis of the site of the primary tumor showed that the CR rate was best in the GU non-BP site (62%) and worst in PM cases (35%). The overall survival and DFS rate were 18% and 15%, respectively. The GU non-BP patients had a DFS rate of 50%, while the rate for all other sites varied between 12% and 18%. A total of 24 patients remained in CCR. The major…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Recurrent, refractory and metastatic RMS represents one of the persistent clinical therapeutic challenges and unmet clinical need, with improvement in 5-year survival experiencing one of the smallest increases of all pediatric and AYA cancers.
“of which recurrent, refractory and metastatic RMS represents one of the persistent clinical therapeutic challenges and unmet clinical need,88–90 with improvement in 5-year survival experiencing one of the smallest increases of all pediatric and AYA cancers.91–95”
From Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation (2023) · cites this paper as [94]
The citation lists haven’t been fetched yet
References 13 · Cited by 83
- Authors
- Koscielniak, E., Rodary, C., Flamant, F., Carli, M., Treuner, J., Pinkerton, C. R., & Grotto, P.
- Affiliations
- Institut Gustave Roussy (FR)
- University of Padua (IT)
- Olgahospital (DE)
- Venue
- Medical and Pediatric Oncology
- Publisher
- Wiley
- Published
- 1992-01
- Volume
- 20
- Issue
- 3
- Pages
- 209-214
- ISSN
- 0098-1532 (ISSN-L)
- 1096-911X
- OpenAlex
- W2083765984
- Cited by
- 83
- References
- 13
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 5 · 2022: 1 · 2020: 1 · 2018: 1 · 2017: 4 · 2016: 2 · 2015: 3 · 2014: 3 · 2013: 4
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Medical and Pediatric Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Childhood Cancer Survivors' Quality of Life
- Keywords
- metastatic rhabdomyosarcoma, alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma, soft tissue sarcoma, childhood cancer, lung metastasis, complete remission, relapse, disease-free survival, overall survival, primary tumor site
- MeSH terms
- Adolescent, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Infant, Male, Remission Induction, Retrospective Studies, Rhabdomyosarcoma, Sarcoma, Soft Tissue Neoplasms, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
